Results 271 to 280 of about 314,420 (315)
Unveiling the role of interleukin-13 in liver fibrosis of chronic hepatitis B patients: Development of a predictive model. [PDF]
PLoS OneBestari MB +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current Treatment Options in Gastroenterology, 2004
Interferon alpha, lamivudine, and adefovir are the three drugs currently approved for the treatment of chronic hepatitis B virus (HBV). There are pros and cons associated with the use of each drug. Individualization of therapy, based upon factors such as patient comorbidities, response to prior therapies, and stage of disease, is recommended.
Stephanie D, Straley, Norah A, Terrault
openaire +2 more sources
Interferon alpha, lamivudine, and adefovir are the three drugs currently approved for the treatment of chronic hepatitis B virus (HBV). There are pros and cons associated with the use of each drug. Individualization of therapy, based upon factors such as patient comorbidities, response to prior therapies, and stage of disease, is recommended.
Stephanie D, Straley, Norah A, Terrault
openaire +2 more sources
Treatment of chronic hepatitis B
Journal of Viral Hepatitis, 2005Summary. In the last years, marked progress has been made in the treatment of chronic hepatitis B. The efficacy of lamivudine, the first nucleoside analogue available, is limited by the high incidence of resistance. Adefovir, which was recently approved has a comparable efficacy with a very low frequency of resistance.
Tarik, Asselah +2 more
openaire +5 more sources
Treatment of chronic hepatitis B
Nature Clinical Practice Gastroenterology & Hepatology, 2006Treatment of chronic hepatitis B has improved substantially over the past five years. Pegylated interferon alpha2a and entecavir have been approved by the FDA and joined the armamentarium of therapies that includes inteferon alpha (IFN-alpha), lamivudine, and adefovir dipivoxil. Several key questions come to mind regarding treatment. Who should receive
Smruti R, Mohanty +2 more
openaire +2 more sources
Interferon in chronic hepatitis B
Antiviral Research, 1994In patients with typical chronic hepatitis B (HBsAg, HBeAg, HBV-DNA-positive), treatment with interferon-alpha must be carried out for 4-6 months on an alternate-day basis and dosage should be not less than 5 million units/square meter of body surface.
G, Saracco, M, Rizzetto, G, Verme
openaire +2 more sources
Prevalence of Hepatic Granulomas in Chronic Hepatitis B
Digestive Diseases and Sciences, 2004An increasing frequency of hepatic granulomas, up to 10%, in chronic hepatitis C patients is reported, and their presence is considered to be a predictor of treatment success. However, there is only one prevalence study on granuloma in chronic hepatitis B, and its significance for treatment outcome is unknown.
Veysel, Tahan +13 more
openaire +4 more sources
The management of chronic hepatitis B
The American Journal of Medicine, 1994The immediate goals of hepatitis B virus (HBV) therapy are to suppress the histologic progression of the disease and diminish infectivity. Although many drugs have been used in the treatment of this condition, only interferon has proven to be consistently effective.
openaire +2 more sources